Rp-8-CPT-cAMPS (sodium)

Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI[1][2].

Product Specifications

CAS Number

[221905-35-7]

UNSPSC

12352005

Target

PKA

Type

Reference compound

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/rp-8-cpt-camps-sodium.html

Purity

99.0

Solubility

DMF : 30 mg/mL (ultrasonic; warming)

Smiles

O[C@H]1[C@](O[C@@](CO2)([H])[C@@]1([H])O[P@@]2([S-])=O)([H])N3C4=NC=NC(N)=C4N=C3SC(C=C5)=CC=C5Cl.[Na+]

Molecular Formula

C16H14ClN5NaO5PS2

Molecular Weight

509.86

References & Citations

[1]Dostmann WR , et, al. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3',5'-cyclic phosphorothioates. J Biol Chem. 1990 Jun 25;265 (18) :10484-91.|[2]Roscioni SS, et, al. PKA and Epac cooperate to augment bradykinin-induced interleukin-8 release from human airway smooth muscle cells. Respir Res. 2009 Sep 29;10 (1) :88.|[3]Chaisakul J, et, al. In vivo and in vitro cardiovascular effects of Papuan taipan (Oxyuranus scutellatus) venom: Exploring "sudden collapse". Toxicol Lett. 2012 Sep 3;213 (2) :243-8.